TMU Innovative Biomedicine Recognized by Boehringer Ingelheim’s Program

Shiow-Lin Pan , the Dean of TMU College of Medical Science and Technology, and her research team developed a new intelligent preclinical medicine development platform that broke the limitation of existing medicines that are too expensive with oblivious effect.

---

Currently, the research team has successfully developed 25 innovative small-molecule lead compounds with an efficacy rate of 60%. Pan remarked that they would focus on adopting those in treatments for cancer and neurodegenerative diseases such as Alzheimer’s disease in the future.

The intelligent preclinical medicine development platform, developed by Pan’s research team, utilizes AI and smart composition technology. All the developed lead compounds have gone efficacy validation in cellular and animal models, with some progressing to organ-like phases and clinical trials. Cancer and neurodegenerative diseases are their primary indications. Experimental verification has confirmed that these lead compounds achieve an efficacy rate of 60%.

Presently, 17 research units and biotech pharmaceutical companies are utilizing the platform. Most excitingly, a spin-off from TMU based on this platform service is expected to be established this year.

Pan reflected that the intelligent preclinical medicine development platform was developed by a team comprising experts from cross-disciplinary, including AI, biology, toxicology, and chemical synthesis. This innovative platform enables them to significantly reduce development timelines, lower costs, and enhance the effectiveness of developed medicines. Looking ahead, Pan and her research team are determined to make good use of the support from Boehringer Ingelheim’s Biomedicine Innovation Program to advance and promote the platform globally.

---

Introduction to the intelligent preclinical medicine development platform